{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-22-000003","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.916885+00:00","generated_at":"2026-06-27T19:15:49.205223+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AtriCure reports preliminary Q4 revenue $73.2M (+27% YoY), guides FY2022 $315-330M","bullets":["Q4 2021 revenue ~$73.2M (+27% YoY); U.S. $61.2M (+29%), Intl $12.0M (+16% as reported).","Full year 2021 revenue $274.3M (+33% YoY); adj. EBITDA loss ~$10M, adj. loss per share ~$1.20.","Management guides FY2022 revenue $315-330M (15-20% growth over 2021), subject to pandemic uncertainty.","Preliminary, unaudited results – final audited results with GAAP reconciliation to follow in later release."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-22-000003","json":"https://secwatch.observer/filing/0001323885-22-000003.json","markdown":"https://secwatch.observer/filing/0001323885-22-000003.md","text":"https://secwatch.observer/filing/0001323885-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000003/0001323885-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000003/atrc-20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:15:49.205223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}